Nuvalent, Inc. (NUVL) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Hold
Based on 18 analysts7.5% Below Target
NUVL trades 7.5% below Wall Street's consensus target of $132.74.
Current Price$123.43
Average Target$132.74
Target
Current
Low$122.85
Median$124.00
High$189.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth+1.3%
(Low)
Analyst Spread49.8%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes NUVL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 18 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
NUVL Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Nuvalent, Inc. (NUVL) has a Wall Street consensus price target of $132.74, based on estimates from 18 covering analysts. With the stock currently trading at $123.43, this represents a potential upside of +7.5%. The company has a market capitalization of $9.08B.
Analyst price targets range from a low of $122.85 to a high of $189.00, representing a 50% spread in expectations. The median target of $124.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Hold, with 8 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, NUVL trades at a trailing P/E of -21.1x. Analysts expect EPS to grow +1.3% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+121.6%
Industry Consensus
Avg Forward P/E
31.0x
(Growth Premium)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KROSKeros Therapeutics, Inc. | $341M | $10.65 | $102.60 | +863.4% | Buy | — | 16 |
 TPSTTempest Therapeutics, Inc. | $5M | $1.23 | — | — | — | — | — |
 MRUSMerus N.V. | $6.8B | $90.00 | $88.69 | -1.5% | Hold | — | 22 |
 ERASErasca, Inc. | $4.3B | $13.67 | $17.50 | +28.0% | Buy | — | 11 |
 TARSTarsus Pharmaceuticals, Inc. | $2.7B | $63.16 | $68.00 | +7.7% | Buy | — | 9 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $282.31 | $584.00 | +106.9% | Buy | — | 16 |
 KRYSKrystal Biotech, Inc. | $10.3B | $348.06 | $336.40 | -3.4% | Buy | 44.9x | 17 |
 ARVNArvinas, Inc. | $495M | $7.67 | $14.75 | +92.3% | Buy | — | 26 |
 KYMRKymera Therapeutics, Inc. | $7.4B | $90.43 | $112.60 | +24.5% | Buy | — | 26 |
 AUPHAurinia Pharmaceuticals Inc. | $2.1B | $16.46 | $12.60 | -23.5% | Buy | 17.1x | 14 |
NUVL — Frequently Asked Questions
Quick answers to the most common questions about buying NUVL stock.
What is the NUVL stock price target for 2026?
The consensus price target for NUVL is $132.74, close to the current price of $123.43 (7.5% implied move). Based on 18 analyst estimates, the stock appears fairly valued near current levels.
Is NUVL a buy, sell, or hold?
NUVL has a consensus rating of "Hold" based on 18 Wall Street analysts. The rating breakdown is mixed, with 10 Hold ratings making up the largest segment. The consensus 12-month price target of $132.74 implies 7.5% upside from current levels.
Is NUVL stock overvalued or undervalued?
NUVL's current price is $123.43 with a consensus target of $132.74 (7.5% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can NUVL stock go?
The most bullish Wall Street analyst has a price target of $189 for NUVL, while the most conservative target is $122.85. The consensus of $132.74 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover NUVL stock?
NUVL is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 10 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the NUVL stock forecast?
The 12-month NUVL stock forecast based on 18 Wall Street analysts shows a consensus price target of $132.74, with estimates ranging from $122.85 (bear case) to $189 (bull case). The median consensus rating is "Hold".
Should I buy NUVL stock?
NUVL appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $132.74 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do NUVL price targets vary so much?
NUVL analyst price targets range from $122.85 to $189, a 50% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $132.74 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare